Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Alaa Ali, Nausheen Ahmed, Soyoung Kim, Matthew Bye, Sayeef Mirza, Alex Gordon Sieg, Christopher Strouse, Kalyan Nadiminti, Priyanka A. Pophali, Rammurti T. Kamble, Lohith Gowda, Cameron J. Turtle, Christine L. Phillips, Marcelo C. Pasquini, Sairah Ahmed, Siddhartha Ganguly, Amy Moskop

Blood (2024) 144 (Supplement 1): 71.

https://doi.org/10.1182/blood-2024-200269

Published: 2024

Journal Articles

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Roshini Pradeep, Zeynep Nazli Benekli, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Sairah Ahmed, Swami P. Iyer

Blood (2024) 144 (Supplement 1): 7776.

https://doi.org/10.1182/blood-2024-202119

Published: 2024

Journal Articles

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Kunhwa Kim, Dai Chihara, Luis E. Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister, Chijioke Nze, Swaminathan P Iyer, Preetesh Jain, Michael Wang, Paolo Strati, Fateeha Furqan, Ayushi Chauhan, Michael R. Green, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4511.1.

https://doi.org/10.1182/blood-2024-205196

Published: 2024

Journal Articles

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2024-206042

Published: 2024

Journal Articles

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Hun Ju Lee, Gregory Ravizzini, Eslam Aboismail, Jenna Wixom, Jared Henderson, Luis E. Fayad, Sairah Ahmed, Ranjit Nair, Jason R. Westin, Swaminathan P Iyer, Chijioke Nze, Ajlan Al Zaki, Francisco Vega, Michael Wang, Christopher R. Flowers, Luis Malpica

Blood (2024) 144 (Supplement 1): 1674.3.

https://doi.org/10.1182/blood-2024-212005

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Eduardo Edelman Saul, Bryan Valcarcel, Amy A. Ayers, Mansoor Noorani, Dai Chihara, Fateeha Furqan, Sairah Ahmed, Swaminathan P Iyer, Sattva S. Neelapu, Luis E. Fayad, F. B. Hagemeister, Chijioke Nze, Preetesh Jain, Michael Wang, Paolo Strati, Ayushi Chauhan, Francisco Vega, Christopher R. Flowers, Jason R. Westin

Blood (2024) 144 (Supplement 1): 4454.

https://doi.org/10.1182/blood-2024-211247

Published: 2024

Journal Articles

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

Elizabeth Rodriguez, Nader Kim El-Mallawany, Sairah Ahmed, Branko Cuglievan, John Andrew Livingston, Christopher R. Flowers, Qian Xiao, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 6359.

https://doi.org/10.1182/blood-2024-208944

Published: 2024

Journal Articles

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

Blood (2024) 144 (Supplement 1): 6420.

https://doi.org/10.1182/blood-2024-211482

Published: 2024

Journal Articles

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Sairah Ahmed, John F. DiPersio, James H Essell, Catherine S. Diefenbach, Miguel Angel Perales, Cristina Castilla-Llorente, Saurabh Dahiya, Sohail Chaudhry, Heng Xu, Yi Liu, Christie Fanton, Zachary Lee, Mario Q. Marcondes, Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk

Blood (2024) 144 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2024-203576

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Alexandra Elias, Rishab Prakash, Ranjit Nair, Luis Malpica, Hun Ju Lee, Eguono Maples, Samantha Carlson, Luis E. Fayad, Krina K. Patel, Sairah Ahmed, Swaminathan P Iyer

Blood (2024) 144 (Supplement 1): 611.

https://doi.org/10.1182/blood-2024-212332

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Blood (2024) 144 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2024-197923

Published: 2024

Journal Articles

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2024-198053

Published: 2024

Journal Articles

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Blood (2024) 144 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2024-207616

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Sairah Ahmed, Avyakta Kallam, Matthew Frigault, Bradley D. Hunter, Sagar S. Patel, David Bernasconi, Soyoung Kim, Tracy Krimmel, Fei Fei Liu, Debasmita Roy, Marcelo C. Pasquini, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 472.

https://doi.org/10.1182/blood-2024-199702

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Karan Gowda, Medha Gupta, Adrian Aguliar, Carlos Cruz, Elizabeth Rodriguez, Sairah Ahmed, Branko Cuglievan, Efstratios Koutroumpakis, Michael E. Roth, Michelle A.T. Hildebrandt

Blood (2024) 144 (Supplement 1): 5128.

https://doi.org/10.1182/blood-2024-211291

Published: 2024

NARROW

Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS)

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Neighborhood-Level Social Determinants of Health and Cardiovascular Burden in Adolescent and Young Adult Patients Treated for Hodgkin Lymphoma

T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center

NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only